Kensey Nash Reviewing TriActiv Distal Protection Marketing Options

Completion of the 50-center, 800-patient, randomized U.S. PRIDE trial of the TriActiv distal protection system in coming months will clear the way for a 510(k) submission by year-end, Kensey Nash says